FDA RATING OF PHARMACOECONOMIC STUDIES ENDORSED BY 59% OF MANAGED CARE PHARMACIES -- MEDTAP's LUCE; HHS IG STUDYING PBM SERVICES TO MCOs
Executive Summary
A majority of pharmacy decisionmakers at large managed care organizations favor peer review and an FDA rating system for pharmacoeconomic studies conducted by pharmaceutical companies, MedTap International CEO Bryan Luce, PhD, told a D.C. Bar Association Health Law Section luncheon May 8.